Literature DB >> 6480825

Factor V (Quebec): a bleeding diathesis associated with a qualitative platelet Factor V deficiency.

P B Tracy, A R Giles, K G Mann, L L Eide, H Hoogendoorn, G E Rivard.   

Abstract

Studies were performed on a French-Canadian family afflicted with a bleeding disorder exhibiting an autosomal dominant inheritance pattern and a severe bleeding diathesis after trauma. Clinical laboratory coagulation tests were unimpressive; the only persistent abnormalities include mild thrombocytopenia and moderately reduced Factor V clotting activities. Some individuals had prolonged Stypven times when platelet-rich plasma was used, suggesting that their platelets could not support functional prothrombinase complex assembly. Detailed studies were performed by use of plasma and isolated, washed platelets from a sister and brother. Bioassay data indicate that both individuals had Factor V activities of approximately 40 and 36% of normal, respectively. A comparison of the Factor V radioimmunoassay and bioassay data on the brother's plasma indicated that the circulating amount of Factor V functional activity was low relative to Factor V antigen concentration (approximately 65-75%). In both individuals, the platelet Factor V functional activities were extremely low (2-4%) relative to antigen levels present as determined by radioimmunoassay. These discrepancies between Factor V activities and antigen concentration do not appear to be due to an unstable Factor V molecule or to the presence of a Factor V or Factor Va inhibitor or inactivator. Kinetics of prothrombin activation by use of purified clotting factors indicated that thrombin-activated platelets from both individuals supported prothrombinase complex assembly identical to controls in the presence of added purified Factor Va. Consequently, their bleeding diathesis appears to reflect their platelet, rather than their plasma, Factor V activity. These results suggest that platelet Factor V is an essential component in maintaining stable and prolonged hemostasis after trauma.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6480825      PMCID: PMC425288          DOI: 10.1172/JCI111531

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  Prothrombin.

Authors:  K G Mann
Journal:  Methods Enzymol       Date:  1976       Impact factor: 1.600

2.  Preparation and partial characterization of two forms of bovine thrombin.

Authors:  R L Lundblad; L C Uhteg; C N Vogel; H S Kingdon; K G Mann
Journal:  Biochem Biophys Res Commun       Date:  1975-09-16       Impact factor: 3.575

Review 3.  Basic mechanisms in blood coagulation.

Authors:  E W Davie; K Fujikawa
Journal:  Annu Rev Biochem       Date:  1975       Impact factor: 23.643

4.  Inherited variants of factor-VIII-related protein in von Willebrand's disease.

Authors:  I R Peake; A L Bloom; J C Giddings
Journal:  N Engl J Med       Date:  1974-07-18       Impact factor: 91.245

Review 5.  Prothrombin structure, activation, and biosynthesis.

Authors:  J W Suttie; C M Jackson
Journal:  Physiol Rev       Date:  1977-01       Impact factor: 37.312

6.  Human prothrombin activation.

Authors:  M R Downing; R J Butkowski; M M Clark; K G Mann
Journal:  J Biol Chem       Date:  1975-12-10       Impact factor: 5.157

7.  Properties of the factor Xa binding site on human platelets.

Authors:  J P Miletich; C M Jackson; P W Majerus
Journal:  J Biol Chem       Date:  1978-10-10       Impact factor: 5.157

8.  Factor X activating enzyme from Russell's viper venom: isolation and characterization.

Authors:  W Kisiel; M A Hermodson; E W Davie
Journal:  Biochemistry       Date:  1976-11-02       Impact factor: 3.162

9.  Patients with congenital factor V deficiency have decreased factor Xa binding sites on their platelets.

Authors:  J P Miletich; D W Majerus; P W Majerus
Journal:  J Clin Invest       Date:  1978-10       Impact factor: 14.808

10.  Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content.

Authors:  H J Weiss; L W Hoyer; F R Rickles; A Varma; J Rogers
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808

View more
  12 in total

1.  The Prothrombinase Complex: Assembly and Function.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

2.  Clotting factor deficiency in early trauma-associated coagulopathy.

Authors:  Sandro B Rizoli; Sandro Scarpelini; Jeannie Callum; Bartolomeu Nascimento; Kenneth G Mann; Ruxandra Pinto; Jan Jansen; Homer C Tien
Journal:  J Trauma       Date:  2011-11

3.  Novel role for galectin-8 protein as mediator of coagulation factor V endocytosis by megakaryocytes.

Authors:  Claudia Zappelli; Carmen van der Zwaan; Daphne C Thijssen-Timmer; Koen Mertens; Alexander B Meijer
Journal:  J Biol Chem       Date:  2012-01-20       Impact factor: 5.157

4.  Current Strategies in Diagnosis of Inherited Storage Pool Defects.

Authors:  Kirstin Sandrock; Barbara Zieger
Journal:  Transfus Med Hemother       Date:  2010-09-15       Impact factor: 3.747

5.  Identification of four novel mutations in F5 associated with congenital factor V deficiency.

Authors:  Sachiko Kanaji; Taisuke Kanaji; Miho Honda; Sachie Nakazato; Kazuo Wakayama; Yoshitomi Tabata; Shoichiro Shibata; Hisashi Gondo; Ikuko Nakamura; Koichi Node; Masanori Miura; Masaharu Miyahara; Takashi Okamura; Fumio Nagumo; Shoichiro Ohta; Kenji Izuhara
Journal:  Int J Hematol       Date:  2008-12-04       Impact factor: 2.490

6.  Proteolysis of plasma-derived factor V following its endocytosis by megakaryocytes forms the platelet-derived factor V/Va pool.

Authors:  F Ayombil; S Abdalla; P B Tracy; B A Bouchard
Journal:  J Thromb Haemost       Date:  2013-08       Impact factor: 5.824

7.  Isolation and study of an acquired inhibitor of human coagulation factor V.

Authors:  M E Nesheim; W L Nichols; T L Cole; J G Houston; R B Schenk; K G Mann; E J Bowie
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

8.  Protease-activated receptor (PAR) 1 and PAR4 differentially regulate factor V expression from human platelets.

Authors:  Matthew Duvernay; Summer Young; David Gailani; Jonathan Schoenecker; Heidi E Hamm; Heidi Hamm
Journal:  Mol Pharmacol       Date:  2013-01-10       Impact factor: 4.436

9.  Inherited trombophilic states and pulmonary embolism.

Authors:  Filip Konecny
Journal:  J Res Med Sci       Date:  2009-01       Impact factor: 1.852

10.  A mutated factor X activatable by thrombin corrects bleedings in vivo in a rabbit model of antibody-induced hemophilia A.

Authors:  Toufik Abache; Alexandre Fontayne; Dominique Grenier; Emilie Jacque; Alain Longue; Anne-Sophie Dezetter; Béatrice Souilliart; Guillaume Chevreux; Damien Bataille; Sami Chtourou; Jean-Luc Plantier
Journal:  Haematologica       Date:  2020-09-01       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.